• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

SGLT2 Inhibitor Therapy Spikes Polycythemia Codes Without Increasing Clonal Disease Detection

by
November 16, 2026
in Health
Reading Time: 7 mins read
0
SGLT2 Inhibitor Therapy Spikes Polycythemia Codes Without Increasing Clonal Disease Detection

SGLT2 Inhibitor Therapy Spikes Polycythemia Codes Without Increasing Clonal Disease Detection

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A large observational study of more than eighty thousand adults treated for diabetes has revealed that sodium-glucose cotransporter 2 inhibitors frequently trigger clinical diagnostic investigations that yield formal diagnostic codes for polycythemia vera, yet these medications do not increase the actual incidence of confirmed clonal hematologic malignancies. The comprehensive investigation, published in Frontiers in Endocrinology by an Israeli clinical research team led by Alena Kirzhner, evaluated electronic health records from the country’s largest integrated healthcare system to settle a persistent clinical question surrounding cardiometabolic therapy. Clinicians have widely noted that patients initiating this modern medication class regularly experience modest elevations in their red blood cell mass, manifested as increases in circulating hemoglobin concentrations and hematocrit percentages. Because extreme elevations in these hematologic indices typically prompt formal hematology consultations and diagnostic workups for underlying bone marrow disorders, earlier anecdotal case reports had suggested that drug therapy might unmask occult hematologic cancers. However, the newly reported epidemiological data demonstrate that the documented surge in diagnostic codes reflects heightened diagnostic surveillance of benign, drug-induced red blood cell expansion rather than any genuine drug-related induction or population-level unmasking of myeloproliferative neoplasms.

Sodium-glucose cotransporter 2 inhibitors have rapidly emerged as foundational therapy across cardiology, nephrology, and diabetology due to their robust ability to improve cardiovascular outcomes, reduce hospitalizations for heart failure, and slow the progression of chronic kidney disease. Concurrently, routine clinical trials and real-world surveillance programs have consistently recorded hemoconcentration among recipients, manifesting as average hematocrit increases between two and four percent across major clinical trials. This hematologic shift stems primarily from mild osmotic diuresis and subsequent intravascular plasma volume contraction, potentially augmented by a physiologic stimulation of erythropoietin production that transiently boosts bone marrow erythropoiesis. In typical clinical practice, this secondary erythrocytosis remains entirely non-clonal, mild, and reversible upon medication adjustment. Nevertheless, when primary care practitioners or attending physicians encounter substantial post-initiation increases in hemoglobin or hematocrit that cross formal diagnostic thresholds, standard clinical guidelines obligate them to consider myeloproliferative neoplasms. Previous medical literature had featured isolated case reports where drug initiation preceded marked erythrocytosis that uncovered previously unsuspected cases of Janus kinase 2 mutated polycythemia vera, fostering clinical uncertainty regarding whether the drug class broadly unmasked or accelerated underlying clonal disease.

To rigorously examine whether this pharmacologic class is truly associated with increased detection or development of clonal hematologic neoplasms, the investigators established a retrospective matched cohort study utilizing longitudinal data from Clalit Health Services. Clalit serves approximately 5.4 million insured individuals, accounting for roughly fifty-two percent of the Israeli population, and maintains comprehensive records encompassing demographic information, primary care visits, hospital claims, diagnostic coding, and dispensing histories extracted via the Clalit Research Data Sharing Platform powered by MDClone. The research cohort included adults aged forty years and older who had a verified diagnosis of diabetes and initiated either a sodium-glucose cotransporter 2 inhibitor or an active comparator drug between January 2015 and July 2025, with longitudinal observation extending through late November 2025. Dipeptidyl peptidase-4 inhibitors were selected as the active comparator because they represent a well-tolerated second-line or third-line glycemic therapy with neutral hematologic effects and an established safety profile. Patients with prior recorded diagnoses of polycythemia vera, essential thrombocythemia, primary myelofibrosis, pre-existing venous thromboembolism, baseline anticoagulant therapy, active non-skin malignancies, or missing baseline laboratory data were systematically excluded from participation.

The initial screening identified 73,147 eligible patients initiating sodium-glucose cotransporter 2 inhibitors and 48,639 eligible patients initiating dipeptidyl peptidase-4 inhibitors across the study period. Because patients prescribed the newer cotransporter inhibitors were systematically more likely to be male, possess higher body mass index values, present with longer diabetes duration, and exhibit greater burdens of cardiovascular and metabolic comorbidities, researchers implemented rigorous one-to-one propensity score matching. Logistic regression models incorporated demographic features, socioeconomic ranking derived from census data, sector classifications, smoking histories, baseline glycated hemoglobin, renal metrics, hematocrit, and nine distinct baseline medication classes. Greedy nearest-neighbor matching without replacement produced an analytical cohort of 40,550 patient pairs that achieved excellent covariate balance across measured clinical characteristics, with standardized mean differences falling comfortably below the accepted threshold of 0.1 for nearly all parameters except a small residual imbalance in serum creatinine that was subsequently adjusted for in extended multivariable models. The matching protocol succeeded in establishing comparable baseline clinical health status while isolating the specific pharmacological exposure across extended follow-up windows.

The primary research outcome centered on newly recorded polycythemia vera confirmed by documented Janus kinase 2 mutation positivity, defined as an International Classification of Diseases, Tenth Revision code of D45 accompanied by an authenticated positive molecular assay. The researchers established this composite primary definition because diagnosis codes in administrative databases frequently capture provisional clinical impressions rather than fully adjudicated pathological entities. Secondary outcomes included newly recorded D45 diagnostic codes regardless of molecular validation, as well as incident diagnostic codes for other major myeloproliferative neoplasms, namely essential thrombocythemia designated by code D47.3 and primary myelofibrosis designated by code D47.4. Time-to-event analyses utilized Cox proportional hazards models with robust sandwich variance estimators clustered on matched pairs to calculate adjusted hazard ratios alongside Fine-Gray subdistribution models that explicitly accounted for all-cause mortality as a competing clinical risk. Covariate models systematically adjusted for age, sex, body mass index, smoking history, and baseline diabetes duration, while extended models additionally integrated index calendar year, baseline creatinine, hemoglobin, and hematocrit levels.

Over the cumulative follow-up period, an administrative diagnosis code for polycythemia vera was documented in 204 patients in the cotransporter inhibitor group and 205 patients in the comparator cohort. However, because the comparator drug class entered the market earlier, patients receiving dipeptidyl peptidase-4 inhibitors contributed substantially more total follow-up time, totaling 269,183 person-years with a median observation of seven years, whereas cotransporter inhibitor recipients contributed 168,137 person-years with a median follow-up of 3.8 years. Consequently, the incidence rate of newly assigned polycythemia vera diagnosis codes was significantly higher among cotransporter inhibitor users, registering at 1.22 cases per 1,000 person-years compared to 0.76 cases per 1,000 person-years in the comparator cohort. This divergence generated an adjusted hazard ratio of 1.69 with a ninety-five percent confidence interval ranging from 1.39 to 2.05. Crucially, testing for proportional hazards revealed that this relative excess was heavily concentrated within the first twelve months following treatment initiation, during which the adjusted hazard ratio reached 3.32 before progressively tapering down to 1.88 across years one through three, and eventually reaching 1.33 after three years of therapy.

When investigators evaluated molecular laboratory results, the apparent diagnostic discrepancy between the two treatment groups dissolved entirely. Among the 409 patients across both cohorts who received a polycythemia vera diagnosis code, roughly half underwent documented molecular testing for Janus kinase 2 mutations, with 98 tested patients in the cotransporter cohort and 106 tested patients in the comparator cohort. Only 64 of these 204 tested patients yielded a positive mutation test, representing just 15.6 percent of all patients who had been assigned a diagnostic code in their medical charts. Furthermore, the test positivity rate among evaluated individuals was substantially lower in the cotransporter group at 24.5 percent compared to 37.7 percent among tested comparator patients. When examining the primary outcome of confirmed mutation-positive disease, exactly 24 cotransporter inhibitor users and 40 comparator users met the criteria, yielding virtually identical incidence rates of 0.14 and 0.15 cases per 1,000 person-years. The corresponding adjusted hazard ratio was 1.00 with a ninety-five percent confidence interval of 0.60 to 1.65, demonstrating no statistical association between drug use and confirmed disease.

The lack of true oncologic divergence extended across all evaluated hematologic endpoints and was consistently reinforced by population comparisons and sensitivity analyses. The incidence of essential thrombocythemia was comparable between the two arms, with 34 recorded events among cotransporter users and 56 among comparator users, yielding an adjusted hazard ratio of 1.07. Similarly, primary myelofibrosis was rare, presenting with seven cases in each cohort and an adjusted hazard ratio of 1.80 that failed to reach statistical significance. When comparing observed disease rates against general population registry benchmarks, administrative coding alone overestimated expected cases forty-fold in the cotransporter cohort and twenty-four-fold in the comparator arm. Conversely, molecularly confirmed polycythemia vera exceeded expected general population incidence by an identical factor of 4.8 in both study groups. Multiple sensitivity evaluations—including multivariable adjustment for calendar prescribing year, exclusion of participants with elevated baseline red blood cell metrics, multiple imputation of missing mutation test results, and inclusion of patients requiring anticoagulants—all preserved hazard ratios centered near unity for confirmed disease.

Longitudinal blood count tracking provided clear mechanistic insight into why administrative diagnostic codes surged following cotransporter inhibitor initiation. Measurements obtained at six and twelve months revealed consistent, class-specific increases in red blood cell parameters. In repeated-measures modeling, cotransporter inhibitor therapy was associated with a mean hemoglobin increase of 0.52 grams per deciliter at six months and 0.63 grams per deciliter at twelve months, alongside hematocrit elevations of 1.85 and 2.10 percentage points, relative to comparator therapy. By the twelfth month of treatment, 16.6 percent of men taking cotransporter inhibitors crossed the World Health Organization diagnostic threshold for polycythemia vera with hematocrit values exceeding 49 percent, compared to only 5.4 percent of men taking the comparator. Among women, 3.3 percent in the cotransporter arm exceeded the 48 percent threshold, compared with 0.8 percent in the comparator arm. Meanwhile, circulating platelet counts and white blood cell levels remained remarkably stable across both cohorts over time, indicating a selective, non-proliferative red blood cell expansion rather than broad, pan-myeloid clonal proliferation.

The authors emphasized that these findings carry substantial clinical relevance for routine diabetes care, while noting several methodological limitations inherent to real-world observational research. Electronic records lacked bone marrow histology, serum erythropoietin levels, and formal diagnostic adjudication from specialist hematologists, meaning that diagnostic coding served as an imperfect surrogate for definitive clinical diagnoses. Approximately one-third of participants also lacked routine follow-up blood count measurements at specified intervals, and molecular testing was recorded in only half of all coded individuals. Nevertheless, the consistency of competing-risk analyses and the pronounced divergence between administrative codes and molecular assays highlight a widespread diagnostic artifact. Because drug-induced hemoconcentration frequently pushes routine hematocrit values above conventional diagnostic thresholds, clinicians frequently enter provisional disease codes while initiating specialist evaluations. The authors concluded that sodium-glucose cotransporter 2 inhibitors do not increase clonal myeloproliferative disorders, advising physicians to recognize drug-related secondary erythrocytosis and pursue a measured, stepwise diagnostic approach rather than presuming bone marrow malignancy.

Subject of Research: Investigation of SGLT2 inhibitor use and the incidence of polycythemia vera and myeloproliferative neoplasms in diabetes patients

Article Title: SGLT2 inhibitor use is associated with more polycythemia vera diagnosis codes but not with JAK2-positive polycythemia vera: a propensity score–matched cohort study

Article References: Kirzhner, A., Ellis, M., Berla, M., abu Khadija, H., Green, H., Haberman, D., Zikry Deitch, M., & Schiller, T. (2026). SGLT2 inhibitor use is associated with more polycythemia vera diagnosis codes but not with JAK2-positive polycythemia vera: a propensity score–matched cohort study. Frontiers in Endocrinology, 17, Article 1979710. https://doi.org/10.3389/fendo.2026.1979710

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1979710

Keywords: SGLT2 inhibitors, DPP4 inhibitors, polycythemia vera, JAK2 mutation, myeloproliferative neoplasms, secondary erythrocytosis, hematocrit, hemoglobin, diabetes care, Clalit Health Services, propensity score matching, essential thrombocythemia, primary myelofibrosis, diagnostic coding, pharmacoepidemiology, observational cohort

News Source: Ophelia Keating. (November 16, 2026). SGLT2 Inhibitor Therapy Spikes Polycythemia Codes Without Increasing Clonal Disease Detection. Scienmag.

Tags: Clalit Health ServicesDiabetes Carediagnostic codingDPP4 inhibitorsessential thrombocythemiahematocrithemoglobinJAK2 Mutationmyeloproliferative neoplasmsobservational cohortpharmacoepidemiologypolycythemia veraprimary myelofibrosispropensity score matchingsecondary erythrocytosisSGLT2 inhibitors
Share12Tweet7Share2ShareShareShare1

Related Posts

Early ICU Mobilization Aids Recovery While Sleep Evidence Remains Inconclusive

Early ICU Mobilization Aids Recovery While Sleep Evidence Remains Inconclusive

November 16, 2026
Urinary Extracellular Vesicles Connect Nutrient Stress to Kidney Inflammation in Diabetes

Urinary Extracellular Vesicles Connect Nutrient Stress to Kidney Inflammation in Diabetes

November 16, 2026

Epigenetic Profiling Identifies High-Risk Subgroup in Pediatric Adrenocortical Carcinoma

November 16, 2026

Angiotensin II Impairs Blood Clotting and Worsens Brain Bleeding in Mice

November 16, 2026

POPULAR NEWS

  • Higher Serum Uric Acid Associated With Obesity in Children With Tonsillar Hypertrophy

    Higher Serum Uric Acid Associated With Obesity in Children With Adenoid and/or Tonsillar Hypertrophy

    29 shares
    Share 12 Tweet 7
  • Clonal Haematopoiesis Associated With Elevated Cardiovascular Risk in MASLD Cohort

    29 shares
    Share 12 Tweet 7
  • Resting-state Brain Age Links Neurodevelopmental Burden to Schizophrenia Severity

    29 shares
    Share 12 Tweet 7
  • Low Preoperative Nutritional Index Predicts ICU Admission After Orthopedic Surgery

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Early ICU Mobilization Aids Recovery While Sleep Evidence Remains Inconclusive

Urinary Extracellular Vesicles Connect Nutrient Stress to Kidney Inflammation in Diabetes

Epigenetic Profiling Identifies High-Risk Subgroup in Pediatric Adrenocortical Carcinoma

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.